|Articles|July 1, 1999

July 1999
Volume 5
Issue 7

The Impact of HMOs on Hospital Use and Cost? A Matter of Interpretation

Author(s)Darrell J. Gaskin, PhD, John Kralewski, PhD

Download PDF: The Impact of HMOs on Hospital Use and Cost? A Matter of Interpretation

Articles in this issue

about 27 years ago

Article

Hospital Expenditures and Utilization: The Impact of HMOs

about 27 years ago

Article

The Cost of Alzheimer's Disease in Managed Care: A Cross-Sectional Study

about 27 years ago

Article

Efficacy and Cost Effectiveness of Lansoprazole Versus Omeprazole in Maintenance Treatment of Symptomatic Gastroesophageal Reflux Disease

about 27 years ago

Article

Payor Cost Savings with Endometrial Ablation Therapy

about 27 years ago

Article

The Food and Drug Administration and Atrial Defibrillation Devices

about 27 years ago

Article

Benign Prostatic Hyperplasia: New Concepts for the Millennium

about 27 years ago

Article

Breast Cancer Prevention: The Role of Antiestrogens

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

The Impact of HMOs on Hospital Use and Cost? A Matter of Interpretation

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

The Impact of HMOs on Hospital Use and Cost? A Matter of Interpretation

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer